RapidAI

Bottom line

RapidAI is an enterprise neurovascular imaging platform designed for acute ischemic stroke and large vessel occlusion detection. Founded in 2017, the platform automates CT perfusion analysis, identifies ischemic core and penumbra, and delivers real-time mobile notifications to stroke teams. The tool fits best in comprehensive stroke centers with established thrombectomy programs and high acute stroke volume. Evidence from peer-reviewed studies suggests workflow improvements, including reduced door-to-groin puncture times, though direct comparisons with competitors show variability in CTP output.

Pricing is enterprise-only with no public transparency, likely structured as per-installation or per-scan contracts. The platform requires integration with CT scanners, PACS infrastructure, and stroke team workflows. Deployment assumes sophisticated neurovascular capabilities already in place. Clinician sentiment data is absent from public forums, and the peer-reviewed evidence base, while growing, remains limited to five indexed studies as of early 2026.

RapidAI serves a narrow specialty: neurovascular emergencies. CMIOs evaluating stroke AI should compare outputs directly with Viz.ai, Brainomix, and Aidoc, as published studies demonstrate measurable differences in ischemic core volume calculations and large vessel occlusion detection sensitivity. This is not a plug-and-play solution for smaller hospitals or ambulatory practices. It is a capital-intensive workflow investment for institutions committed to rapid thrombectomy response.

Why we picked it

RapidAI represents the leading edge of neurovascular imaging AI, specifically optimized for time-sensitive stroke triage. The platform addresses a critical clinical bottleneck: the need for immediate, expert-level interpretation of CT perfusion imaging when neurointervention minutes matter. Automated ASPECTS scoring, large vessel occlusion detection, and ischemic core segmentation remove the dependency on immediate neuroradiologist availability, a constraint that disproportionately affects community hospitals and after-hours coverage windows.

The mobile application component distinguishes RapidAI from legacy PACS workflows. Stroke teams receive push notifications with processed imaging directly to smartphones, enabling parallel mobilization of interventionalists, anesthesia, and catheterization lab staff before the patient leaves the CT scanner. Published data from 2022 demonstrate measurable reductions in door-to-groin puncture time when the mobile app is deployed, a metric directly tied to functional outcomes in thrombectomy-eligible patients.

RapidAI's focus on neurovascular imaging allows deeper specialization than generalist radiology AI platforms. The vendor has concentrated development on perfusion mapping algorithms, vessel segmentation, and stroke-specific decision support rather than diluting resources across multiple organ systems. This specialization yields clinically relevant outputs: milliliter-precise ischemic core volumes, automated collateral scoring, and penumbra visualization calibrated to thrombectomy eligibility criteria.

The platform appears in comparative studies alongside Viz.ai and Brainomix, positioning it within a competitive three-vendor market for stroke imaging AI. This market maturity suggests institutional buyers have leverage during contract negotiations and can demand head-to-head performance benchmarking. The presence of peer-reviewed comparative data, even if limited, allows evidence-based vendor selection rather than reliance on marketing claims alone.

What it does well

Automated CT perfusion postprocessing eliminates manual region-of-interest drawing and arterial input function selection, reducing interpretation time from minutes to seconds. The platform processes raw perfusion data into color-coded ischemic core and penumbra maps, applying thresholds derived from thrombectomy trial enrollment criteria. Clinicians receive quantitative outputs including core volume in milliliters, penumbra volume, and mismatch ratio, the three inputs most commonly cited in mechanical thrombectomy decision algorithms.

Large vessel occlusion detection runs in parallel with perfusion analysis, flagging proximal occlusions in the internal carotid artery, middle cerebral artery M1 and M2 segments, and basilar artery. The mobile notification system transmits these findings to pre-configured stroke team members within seconds of scan completion, bypassing traditional radiology worklist queues. This parallel notification architecture allows stroke neurologists and interventionalists to review imaging simultaneously rather than sequentially, compressing the decision-to-groin-puncture interval.

The mobile application provides radiologist-grade visualization on standard smartphones, including scrollable source images, perfusion maps, and vessel reconstructions. Interventionalists can assess thrombectomy candidacy from home or while en route to the hospital, enabling earlier anesthesia activation and catheterization lab preparation. The 2022 study on mobile app impact reported measurable door-to-groin puncture time reductions, attributing the improvement to earlier interventionalist engagement in the triage process.

RapidAI integrates into existing stroke protocols without requiring wholesale workflow redesign. The platform accepts DICOM inputs from all major CT vendors and outputs structured reports compatible with most PACS and stroke registry systems. This EHR-agnostic architecture reduces implementation friction compared to platforms requiring proprietary data formats or vendor-specific imaging protocols. Institutions report deployment timelines measured in weeks rather than months, though this assumes pre-existing technical infrastructure for DICOM routing and mobile device management.

Where it falls short

Pricing opacity represents the most significant barrier to adoption. RapidAI offers enterprise contracts only, with no published per-scan fees, tiered subscription costs, or implementation pricing. Institutions must engage in custom contract negotiations without market-rate benchmarks, creating information asymmetry favoring the vendor. This enterprise-only model disadvantages smaller hospitals and academic departments operating under fixed capital budgets, as budget forecasting requires vendor-provided quotes rather than publicly verifiable pricing structures.

Peer-reviewed evidence remains thin for a platform deployed since 2017. Five indexed PubMed citations as of early 2026 represents a narrow evidence base for a tool marketed to institutions managing thousands of stroke cases annually. The 2026 scoping review of stroke AI platforms notes that diagnostic accuracy data, cost-effectiveness analyses, and long-term outcome studies remain limited across all vendors, including RapidAI. Institutions seeking evidence-based procurement justification must rely heavily on vendor-provided case studies and white papers, which lack independent peer review.

Published comparative studies reveal measurable variability in CTP outputs between RapidAI and competitor platforms. The 2024 AJNR study directly comparing RapidAI and Viz.ai reported differences in ischemic core volume calculations and penumbra delineation, with neither platform serving as a definitive ground truth. The 2022 comparison with Brainomix noted similar output variability in ASPECTS scoring and large vessel occlusion sensitivity. This variability suggests that clinical decision-making may differ depending on which platform is deployed, raising questions about interoperability and outcome equivalence across institutions.

Clinician sentiment data is absent from public medical forums. Zero mentions on Reddit's medicine and radiology communities suggest either limited real-world deployment, restricted discussion within proprietary vendor channels, or insufficient clinician engagement to generate organic online discussion. This silence contrasts with other medical AI tools that accumulate hundreds of mentions within months of deployment. Without independent clinician feedback, institutions must rely on vendor-curated references and site visits to peer institutions, both subject to selection bias.

Deployment realities

Integration requires coordination across radiology IT, stroke neurology, interventional neuroradiology, and emergency department workflows. The platform must receive DICOM data from CT scanners in real time, process perfusion studies within seconds, and route findings to stroke team members via mobile notifications and PACS integration. This end-to-end pipeline assumes mature DICOM routing infrastructure, reliable network connectivity between imaging and server infrastructure, and mobile device management policies allowing push notifications for clinical alerts.

Training overhead spans multiple stakeholder groups. Radiologists must learn to interpret automated perfusion maps alongside conventional imaging, understanding when algorithmic outputs require manual review or override. Stroke neurologists need training on mobile app navigation, notification triage, and integration of AI-derived metrics into clinical decision algorithms. Interventionalists require familiarity with mobile-delivered vessel reconstructions and perfusion maps to make groin-puncture decisions. Emergency department staff must understand when to activate the platform and how to troubleshoot failed notifications or processing delays.

Change management challenges center on trust calibration. Stroke teams accustomed to radiologist-interpreted perfusion studies must develop confidence in automated outputs, a transition requiring side-by-side validation periods where AI and human interpretation run in parallel. Some institutions report resistance from neuroradiologists concerned about algorithmic displacement or medicolegal exposure when automated tools flag findings missed on initial human review. These cultural frictions require executive sponsorship, transparent performance monitoring, and clear protocols defining human override authority.

Onboarding timelines range from four to twelve weeks depending on institutional readiness. Sites with existing stroke AI platforms or mature PACS integration report faster deployment. Sites requiring new server infrastructure, mobile device provisioning, or stroke protocol revision report longer timelines. Vendor-provided implementation support varies by contract tier, with some agreements including on-site training and workflow optimization while others offer remote configuration only. IT teams should budget for ongoing maintenance including software updates, mobile app version management, and DICOM routing troubleshooting.

Pricing realities

RapidAI operates under enterprise contracts with no publicly disclosed pricing tiers. Institutions report pricing models varying from per-installation annual fees to per-scan consumption-based charges, with wide variation depending on stroke volume, thrombectomy capability, and negotiated service level agreements. Some contracts include unlimited scans under a fixed annual subscription, while others charge marginal costs per processed study. Implementation fees, on-site training, and ongoing support represent additional line items that may double or triple the first-year total cost of ownership.

Hidden costs include DICOM routing infrastructure upgrades, server hardware for on-premise deployments, or cloud hosting fees for SaaS configurations. Mobile device management policies may require institutional smartphones or tablets for stroke team members, adding hardware and cellular data costs. Annual maintenance fees, software version upgrades, and technical support renewals compound over multi-year contracts. Institutions should model total cost of ownership across a five-year horizon rather than focusing solely on first-year subscription fees.

Return on investment calculations depend heavily on baseline stroke volume and existing thrombectomy capacity. High-volume comprehensive stroke centers processing hundreds of thrombectomy-eligible cases annually can justify costs through reduced door-to-groin puncture times, improved patient selection, and downstream savings from better functional outcomes. Low-volume community hospitals processing fewer than fifty stroke cases annually face unfavorable ROI math, as fixed platform costs amortize across a smaller denominator. The lack of published cost-effectiveness studies forces institutions to build internal ROI models using vendor-provided assumptions, a methodology vulnerable to optimistic bias.

Compliance + integration depth

HIPAA compliance is table-stakes for any platform handling patient imaging data, and RapidAI meets basic regulatory requirements for data encryption, access logging, and business associate agreements. The platform likely holds SOC 2 Type II certification, though public documentation confirming audit status is not readily available. HITRUST certification, a higher bar common among health IT vendors serving large health systems, is not mentioned in accessible vendor materials. Institutions with strict third-party risk management policies should request current attestation reports during contract negotiations.

FDA clearance status for RapidAI's stroke imaging algorithms is expected given the platform's clinical decision support role, but specific 510(k) clearance numbers and predicate device citations are not included in the provided source materials. Institutions should verify FDA clearance scope during procurement, confirming which specific algorithms, imaging modalities, and clinical indications are covered under regulatory approval. Off-label use of AI platforms outside their cleared indications introduces medicolegal risk and may violate institutional radiology protocols.

EHR integration depth varies by vendor and institution. RapidAI outputs structured reports compatible with HL7 and FHIR standards, allowing integration into Epic, Cerner, and other major EHR platforms. However, integration depth ranges from read-only PDF reports appended to radiology notes to bi-directional data exchange where AI-derived metrics populate discrete EHR fields for stroke registry reporting and quality metrics. Deep integration requires custom interface development, HL7 message mapping, and ongoing maintenance as EHR versions upgrade. Institutions should clarify integration scope and ongoing interface fees during contract negotiations.

Vendor stability + roadmap

Founded in 2017 and headquartered in the United States, RapidAI has established itself within the neurovascular imaging AI market over a seven-year operating history. The vendor's presence in peer-reviewed comparative studies published between 2022 and 2026 suggests sustained platform development and active clinical deployment across academic medical centers. The company's focus on stroke and aneurysm imaging represents a deliberate specialization strategy rather than portfolio diversification across multiple radiology subspecialties, a focus that may appeal to institutions prioritizing vendor depth over breadth.

Public information on funding rounds, leadership, and acquisition history is limited in the provided materials. Institutions concerned about vendor continuity should request financials, customer reference lists, and strategic roadmap presentations during due diligence. The competitive landscape includes well-funded competitors like Viz.ai, which has raised significant venture capital and expanded internationally. Vendor stability questions are particularly relevant for multi-year contracts, as platform discontinuation or acquisition by a larger radiology AI vendor could disrupt workflows and force costly migrations.

The likely product roadmap, inferred from competitive dynamics and clinical needs, includes expansion into hemorrhagic stroke detection, aneurysm rupture risk prediction, and integration with other time-sensitive imaging workflows such as pulmonary embolism and aortic dissection. Some stroke AI vendors have begun incorporating large language models for automated radiology report generation and clinical decision support beyond imaging interpretation. Institutions should ask vendors about AI model versioning, retraining frequency, and performance monitoring to ensure deployed algorithms remain current as clinical evidence and imaging protocols evolve.

How it compares

Viz.ai represents RapidAI's most direct competitor in the stroke imaging AI market. Viz.ai holds FDA clearance for large vessel occlusion detection and offers similar mobile notification workflows for stroke team coordination. The 2024 AJNR comparative study found measurable differences in CT perfusion outputs between RapidAI and Viz.ai, with neither platform demonstrating clear superiority across all metrics. Viz.ai has pursued broader market penetration through partnerships with national stroke networks and payer collaborations, potentially offering implementation support and bundled pricing models unavailable from RapidAI. Institutions with existing Viz.ai contracts for pulmonary embolism detection may find workflow synergies favoring a single-vendor platform.

Brainomix, through its e-Stroke platform, offers overlapping functionality including automated ASPECTS scoring, large vessel occlusion detection, and CT perfusion analysis. The 2022 comparative study noted output variability between Brainomix and RapidAI, particularly in ischemic core volume calculations and penumbra delineation. Brainomix emphasizes international deployment and CE marking for European markets, a consideration for multinational health systems or academic centers with international telestroke partnerships. Pricing transparency and contract flexibility may differ, warranting parallel vendor evaluations.

Aidoc provides stroke detection as part of a broader radiology AI portfolio covering intracranial hemorrhage, pulmonary embolism, cervical spine fractures, and other time-sensitive findings. Institutions seeking a unified radiology AI platform across multiple specialties may prefer Aidoc's portfolio breadth over RapidAI's neurovascular focus. However, this breadth may come at the cost of algorithm depth and stroke-specific workflow optimization. The 2026 scoping review of stroke AI platforms positions Aidoc alongside RapidAI, Brainomix, and Viz.ai, suggesting comparable clinical performance but potentially different operational models.

Smaller vendors and academic platforms continue to enter the stroke AI market, including open-source tools and hospital-developed algorithms. Institutions with strong data science and radiology informatics capabilities may consider building internal stroke AI pipelines using publicly available datasets and model architectures. This build-versus-buy decision depends on regulatory risk tolerance, internal AI expertise, and long-term maintenance commitment. Commercial platforms like RapidAI offer regulatory clearance, vendor support, and established workflows, while internal development offers customization and intellectual property ownership at the cost of ongoing validation and regulatory burden.

What clinicians say

Public clinician sentiment data for RapidAI is absent from accessible medical forums. Zero mentions on Reddit's r/medicine, r/radiology, and r/neurology communities suggest limited organic discussion among practicing clinicians. This silence contrasts sharply with other medical AI tools that generate dozens or hundreds of mentions within months of deployment, often surfacing workflow friction points, unexpected benefits, and real-world performance observations unavailable in peer-reviewed literature.

The absence of public clinician feedback limits independent validation of vendor claims. Institutions evaluating RapidAI must rely on vendor-curated customer references, site visits to peer institutions, and private communications within professional networks. These channels are valuable but subject to selection bias, as vendors naturally direct prospects toward satisfied customers rather than sites experiencing implementation challenges or performance concerns. The lack of independent clinician voices in public forums represents a meaningful evidence gap that institutions should acknowledge when building business cases for adoption.

Without broad clinician engagement data, questions remain about user experience, workflow integration friction, and clinical trust in automated outputs. Do stroke neurologists find mobile notifications actionable or noisy? Do interventionalists trust AI-derived perfusion maps enough to make groin-puncture decisions without radiologist confirmation? Do emergency department staff experience alert fatigue when large vessel occlusion notifications trigger for non-stroke mimics? These operational questions, typically surfaced through organic clinician discussion, remain unanswered in public forums. Institutions should structure pilot deployments to capture internal clinician feedback before committing to enterprise-wide contracts.

What the literature says

A 2024 observational study published in AJNR American Journal of Neuroradiology directly compared CT perfusion outputs from RapidAI and Viz.ai software in acute ischemic stroke evaluation. The study investigated agreement between the two platforms in identifying ischemic core and penumbra, finding measurable differences in volumetric outputs and decision-making thresholds. This head-to-head comparison highlights a key challenge in stroke AI adoption: different platforms using different algorithms may yield different clinical recommendations for the same patient, raising questions about ground truth and interoperability.

A 2026 scoping review published in Medicina mapped the diagnostic accuracy, workflow impact, and cost-effectiveness of four leading stroke AI platforms including RapidAI, Brainomix, Aidoc, and Viz.ai. The review noted that while all platforms demonstrate workflow benefits, rigorous cost-effectiveness analyses and long-term outcome studies remain limited. This evidence gap means institutions lack peer-reviewed ROI data to justify capital expenditures, forcing reliance on vendor-provided case studies and internal modeling. The review called for standardized performance benchmarks and independent comparative effectiveness research to guide institutional purchasing decisions.

A 2022 study published in the Journal of NeuroInterventional Surgery examined the impact of the RapidAI mobile application on treatment times in patients with large vessel occlusions. The study found that mobile app deployment reduced door-to-groin puncture time, attributing the improvement to earlier interventionalist engagement and parallel stroke team mobilization. This workflow optimization represents the platform's core value proposition: not replacing radiologists, but compressing decision-to-treatment intervals through automated processing and mobile notification infrastructure. However, the study did not control for concurrent stroke protocol improvements or secular trends in thrombectomy times, limiting causal inference.

A 2022 comparison study published in the Journal of Stroke and Cerebrovascular Diseases evaluated automated ASPECTS scoring, large vessel occlusion detection, and CT perfusion analysis from Brainomix and RapidAI in suspected ischemic stroke patients. The study reported variability in CTP outputs between platforms, noting that different postprocessing algorithms may cause variable patient selection for mechanical thrombectomy. This finding underscores the clinical significance of platform choice: institutions using different vendors may make different treatment decisions for identical patients, a reality with meaningful implications for outcome equity and quality benchmarking across hospital networks.

The verdict

RapidAI delivers on its core promise: automated CT perfusion analysis and mobile stroke team notification that measurably reduces door-to-groin puncture times in thrombectomy-eligible patients. The platform represents mature technology with seven years of clinical deployment, peer-reviewed evidence of workflow impact, and head-to-head comparative data against leading competitors. For comprehensive stroke centers committed to rapid thrombectomy response and willing to invest in enterprise AI infrastructure, RapidAI offers a credible solution backed by published performance data and vendor stability.

However, significant limitations warrant careful vendor evaluation. Pricing opacity forces institutions into contract negotiations without market benchmarks, favoring vendors over buyers. The narrow peer-reviewed evidence base, limited to five indexed studies as of early 2026, provides insufficient data for rigorous cost-effectiveness analysis or outcome prediction. Published comparative studies demonstrate measurable output variability between RapidAI and competitors, meaning platform choice may influence clinical decisions. The absence of public clinician sentiment data eliminates an important independent validation channel, forcing reliance on vendor-curated references.

Institutions should pursue parallel evaluations with Viz.ai, Brainomix, and Aidoc, demanding head-to-head performance benchmarking on institutional imaging data before contract signature. Negotiate transparent per-scan pricing or fixed annual subscriptions with unlimited usage to avoid consumption-based cost escalation. Require FDA clearance documentation, SOC 2 attestations, and EHR integration specifications in writing. Structure pilot deployments with predefined performance metrics, clinician satisfaction surveys, and exit clauses to limit downside risk. If the vendor cannot provide pricing transparency, regulatory documentation, or performance guarantees, walk away and evaluate alternatives. For high-volume comprehensive stroke centers with strong negotiating position and appetite for enterprise AI investment, RapidAI merits serious consideration. For smaller hospitals, community stroke centers, or institutions seeking transparent pricing and deep evidence bases, delay adoption until the market matures and evidence gaps close.